Filing Flows

Filing Flows › 8-K events › Accendra Health

Accendra Health: departure or appointment of directors and officers

Form 8-K filed Nov 3, 2026 · items 5.02

What the filing says

Bernocchi, the Company’s Executive Vice President, Chief Operating Officer, entered into a transition agreement with the Company under which Mr. Bernocchi will cease to be an executive officer and will serve as Strategic Advisor to the Chief Executive Officer until December 31, 2026, unless his employment ends earlier.

Read the filing on SEC EDGAR →

What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Accendra Health at a glance

Latest quarterQ3 2026
Revenue$601.8M
Revenue Y/Y-14%
Operating margin0.2%
IndustryWholesale-Medical, Dental & Hospital Equipment & Supplies

Accendra Health, Q3 2026: revenue $602M (-14% year over year), operating margin 0.2%. The chart follows the revenue to costs, profit and cash.

Accendra Health: every quarter, Q/Q and Y/Y, holders and guidance →

Accendra Health’s other material 8-Ks

Other recent ceo changes

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.